{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:50:10Z","timestamp":1788364210058,"version":"build-2803163510"},"reference-count":81,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) have transformed cancer therapeutics yet frequently induce renal injury and multi-organ immune-related adverse events (irAEs) that present substantial clinical management challenges. Critical evidence gaps persist regarding dynamic immune microenvironment interactions and optimal organ-protective strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>We systematically evaluated ICI efficacy and safety profiles concerning renal and multi-organ outcomes in cancer patients, with particular focus on underlying mechanisms and protective interventional approaches.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a comprehensive, systematic literature search across PubMed, Cochrane Library, Embase, Web of Science, and Scopus (January 2000-December 2025) to inform a narrative synthesis. This narrative review approach integrates evidence from diverse study designs (experimental, observational, and clinical) to generate mechanistic hypotheses and clinical insights, rather than to estimate pooled effect sizes. Two independent reviewers performed structured study selection and quality appraisal using established tools (Cochrane RoB 2.0, ROBINS-I, GRADE) to enhance transparency and evaluate evidence certainty, acknowledging that formal meta-analysis was precluded by methodological heterogeneity. We employed narrative synthesis methodologies organized around mechanistic themes (PD-1\/PD-L1 signaling, mTORC1-autophagy, cGAS-STING) to integrate translational and clinical evidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our analysis of 68 included studies (n=15,392 participants) establishes that ICIs associate with acute kidney injury manifestations\u2014notably tubulointerstitial nephritis\u2014and multi-organ irAEs including myocarditis. Mechanistic investigations reveal PD-1\/PD-L1 pathway disruption, metabolic dysregulation, and immune cell heterogeneity as central pathways, though quantitative effect estimates demonstrated significant interstudy variability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Tumor immunotherapy substantially impacts renal and multi-organ homeostasis, supported by moderate-certainty evidence. Immune microenvironment-targeted protective strategies emerge as crucial for optimizing therapeutic outcomes, while future investigations should prioritize biomarker-guided precision approaches to balance efficacy and safety considerations. The observed heterogeneity in nephrotoxicity patterns suggests tissue-specific immune microenvironment interactions warranting single-cell resolution analysis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1777694","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T05:38:26Z","timestamp":1783661906000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of tumor immunotherapy on kidney injury and multi-organ outcomes: a mechanistic and clinical perspective"],"prefix":"10.3389","volume":"17","author":[{"given":"Lan","family":"Jiang","sequence":"first","affiliation":[{"name":"Department of Oncology, Huangshi Central Hospital, Affiliated Hospital of Hubei Polytechnic University","place":["Huangshi, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[{"name":"Medical Services Department, Huangshi Second Hospital","place":["Huangshi, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihong","family":"Xiong","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Tianyou Hospital Affiliated to Wuhan University of Science and Technology","place":["Wuhan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumei","family":"Min","sequence":"additional","affiliation":[{"name":"Medical Records Department, Hubei Provincial Hospital of Direct Affiliation (Hubei Provincial Rehabilitation Hospital)","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Gong","sequence":"additional","affiliation":[{"name":"Medical Examination Center, Hubei Provincial Hospital of Integrated Chinese and Western Medicine Wuhan","place":["Hubei, Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2025.01.021","article-title":"Pathological findings of immunotherapy-induced nephrotoxicity in a humanized immune system mouse model","volume":"107","author":"Asby","year":"2025","journal-title":"Kidney Int"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2019.11.26","article-title":"Toxicity of tumor immune checkpoint inhibitors-more attention should be paid","volume":"8","author":"Liu","year":"2019","journal-title":"Transl Lung Cancer Res"},{"key":"B3","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1186\/s12911-025-03142-0","article-title":"Development and validation of interpretable machine learning models for predicting AKI risk in patients treated with PD-1\/PD-L1: a retrospective study","volume":"25","author":"Liu","year":"2025","journal-title":"BMC Med Inform Decis Mak"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14093231","article-title":"Immune checkpoint inhibitor-associated acute kidney injury: a single-center experience of biopsy-proven cases","volume":"14","author":"Kommer","year":"2025","journal-title":"J Clin Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ejim.2023.05.034","article-title":"Incidence, mortality, and risk factors of acute kidney injury after immune checkpoint inhibitors: Systematic review and meta-analysis of real-world evidence","volume":"115","author":"Xie","year":"2023","journal-title":"Eur J Intern Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1173952","article-title":"Incidence and risk factors of acute kidney injury in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"14","author":"Liu","year":"2023","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfae184","article-title":"Immune checkpoint inhibitor-associated nephritis-treatment standard","volume":"39","author":"Barbir","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000543323","article-title":"Immune checkpoint inhibitor-related acute kidney injury: Management and challenges","volume":"14","author":"Youssef","year":"2025","journal-title":"Am J Nephrol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1080\/0886022X.2025.2590283","article-title":"Anticancer drug-induced nephrotoxicity: biopsy-proven patterns and outcomes across chemotherapy, targeted therapy, and immune checkpoint inhibitors","volume":"47","author":"Tian","year":"2025","journal-title":"Ren Fail"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.14490","article-title":"A potential mechanism of anticancer immune response coincident with immune-related adverse events in patients with renal cell carcinoma","volume":"40","author":"Kato","year":"2020","journal-title":"Anticancer Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-20-0969","article-title":"Regulatory T-cell transcriptomic reprogramming characterizes adverse events by checkpoint inhibitors in solid tumors","volume":"9","author":"Grigoriou","year":"2021","journal-title":"Cancer Immunol Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12964-021-00742-x","article-title":"The role of PD-L1 in the immune dysfunction that mediates hypoxia-induced multiple organ injury","volume":"19","author":"Sun","year":"2021","journal-title":"Cell Commun Signal"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/HCO.0000000000000622","article-title":"Immune checkpoint inhibitor myocarditis","volume":"34","author":"Raikhelkar","year":"2019","journal-title":"Curr Opin Cardiol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13901","article-title":"Molecular mechanisms of glucocorticoid resistance","volume":"53","author":"Huang","year":"2023","journal-title":"Eur J Clin Invest"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.624547","article-title":"Variable expression of programmed cell death protein 1-ligand 1 in kidneys independent of immune checkpoint inhibition","volume":"11","author":"Hakroush","year":"2020","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/978-981-15-3266-5_3","article-title":"Roles of PD-1\/PD-L1 pathway: signaling, cancer, and beyond","volume":"1248","author":"Ai","year":"2021","journal-title":"Adv Exp Med Biol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.prro.2022.07.003","article-title":"Use of glucocorticoids in patients with cancer: Potential benefits, harms, and practical considerations for clinical practice","volume":"13","author":"Kim","year":"2023","journal-title":"Pract Radiat Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3779\/j.issn.1009-3419.2019.10.02","article-title":"The use of glucocorticoid in the management of adverse effects related to immunocheckpoint inhibitors","volume":"22","author":"Wang","year":"2019","journal-title":"Zhongguo Fei Ai Za Zhi"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1088\/1758-5090\/ae0dba","article-title":"From organ to system: multiorgan-on-a-chip platforms as next-generation biomedical simulators","volume":"17","author":"Chen","year":"2025","journal-title":"Biofabrication"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/mabi.202500240","article-title":"Vascularized tumor-on-a-chip model as a platform for studying tumor-microenvironment-drug interaction","volume":"25","author":"Kim","year":"2025","journal-title":"Macromol Biosci"},{"key":"B21","doi-asserted-by":"publisher","first-page":"5598627","DOI":"10.1155\/2021\/5598627","article-title":"Transcriptional profiling reveals kidney neutrophil heterogeneity in both healthy people and ccRCC patients","volume":"1248","author":"Meng","year":"2021","journal-title":"J Immunol Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-095135","article-title":"Superior vena cava isolation added to pulmonary vein isolation enhances outcomes in paroxysmal atrial fibrillation: a meta-analysis with trial sequential analysis","volume":"15","author":"Guan","year":"2025","journal-title":"BMJ Open"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.99910","article-title":"Laminar airflow in penile prosthesis surgery and infection: An empty systematic review","volume":"17","author":"Shafiq","year":"2025","journal-title":"Cureus"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12041349","article-title":"Clinicopathological features of kidney injury related to immune checkpoint inhibitors: A systematic review","volume":"12","author":"Xu","year":"2023","journal-title":"J Clin Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.29063\/ajrh2025\/v29i5s.3","article-title":"Effect of tacrolimus plus mycophenolate mofetil in the therapy of children with steroid-resistant nephrotic syndrome","volume":"29","author":"Zhao","year":"2025","journal-title":"Afr J Reprod Health"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1159\/000538274","article-title":"Association of proton pump inhibitor use and immune checkpoint inhibitor-mediated acute kidney injury: A meta-analysis and a review of related outcomes","volume":"55","author":"Mohan","year":"2024","journal-title":"Am J Nephrol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02895-x","article-title":"Single-cell transcriptomic analyses reveal distinct immune cell contributions to epithelial barrier dysfunction in checkpoint inhibitor colitis","volume":"30","author":"Thomas","year":"2024","journal-title":"Nat Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11101422","article-title":"The emerging roles of mTORC1 in macromanaging autophagy","volume":"11","author":"Dossou","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S543273","article-title":"Crosstalk between cell death and the cGAS-STING pathway in sepsis-associated acute lung injury","volume":"18","author":"Li","year":"2025","journal-title":"J Inflammation Res"},{"key":"B30","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12964-021-00738-7","article-title":"Mitochondrial DNA leakage induces odontoblast inflammation via the cGAS-STING pathway","volume":"19","author":"Zhou","year":"2021","journal-title":"Cell Commun Signal"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.902256","article-title":"Compartmentalization of intrarenal programmed cell death protein 1-ligand 1 and its receptor in kidney injury related to immune checkpoint inhibitor nephrotoxicity","volume":"9","author":"Tampe","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100878","article-title":"CD8+ T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy","volume":"4","author":"Huseni","year":"2023","journal-title":"Cell Rep Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.ccell.2021.02.015","article-title":"Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma","volume":"39","author":"Bi","year":"2021","journal-title":"Cancer Cell"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20201979","article-title":"Immune checkpoint inhibitors","volume":"218","author":"Kroemer","year":"2021","journal-title":"J Exp Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.201810035","article-title":"Immune checkpoint inhibitors","volume":"218","author":"Hui","year":"2019","journal-title":"J Cell Biol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1548053","article-title":"Tissue-resident macrophages and renal diseases: landscapes and treatment directions","volume":"16","author":"Qu","year":"2024","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-024-01190-6","article-title":"Depleting profibrotic macrophages using bioactivated in vivo assembly peptides ameliorates kidney fibrosis","volume":"21","author":"Ouyang","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.18773\/austprescr.2019.012","article-title":"Immune checkpoint inhibitors in Malignancy","volume":"42","author":"Ardolino","year":"2019","journal-title":"Aust Prescr"},{"key":"B39","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s11912-021-01070-6","article-title":"Cardiotoxicity of immune checkpoint inhibitors","volume":"23","author":"Patel","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"B40","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s11936-019-0731-6","article-title":"Cardiotoxicity of immune checkpoint inhibitors","volume":"21","author":"Zhang","year":"2019","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14051145","article-title":"Immune checkpoint inhibitors-associated cardiotoxicity","volume":"14","author":"Li","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2019.03.012","article-title":"Immune checkpoint inhibitor toxicities","volume":"94","author":"Marin-Acevedo","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0000000000000988","article-title":"Immune checkpoint inhibitors-related cardiotoxicity","volume":"27","author":"Konala","year":"2020","journal-title":"Am J Ther"},{"key":"B44","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1146\/annurev-physiol-060821-014008","article-title":"Alcohol-associated tissue injury: current views on pathophysiological mechanisms","volume":"84","author":"Simon","year":"2024","journal-title":"Annu Rev Physiol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3390\/cells12232749","article-title":"Th17 cells, glucocorticoid resistance, and depression","volume":"12","author":"Khantakova","year":"2023","journal-title":"Cells"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202205409","article-title":"Manganese-based tumor immunotherapy","volume":"35","author":"Zhang","year":"2023","journal-title":"Adv Mater"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.4158\/EP-2019-0475","article-title":"A novel glucocorticoid receptor mutation in primary generalized glucocorticoid resistance disease","volume":"26","author":"Ma","year":"2020","journal-title":"Endocr Pract"},{"key":"B48","doi-asserted-by":"publisher","first-page":"4540","DOI":"10.1038\/s41467-021-24811-4","article-title":"G\u03b1q activation modulates autophagy by promoting mTORC1 signaling","volume":"12","author":"Cabezudo","year":"2021","journal-title":"Nat Commun"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20200661","article-title":"Sophoricoside ameliorates cardiac hypertrophy by activating AMPK\/mTORC1-mediated autophagy","volume":"40","author":"Gao","year":"2020","journal-title":"Biosci Rep"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1002\/bies.202000187","article-title":"Does mTORC1 inhibit autophagy at dual stages?: a possible role of mTORC1 in late-stage autophagy inhibition in addition to its known early-stage autophagy inhibition","volume":"43","author":"Ramaian Santhaseela","year":"2021","journal-title":"Bioessays"},{"key":"B51","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12964-024-01499-9","article-title":"Arginyltransferase 1 modulates p62-driven autophagy via mTORC1\/AMPk signaling","volume":"22","author":"Bonnet","year":"2024","journal-title":"Cell Commun Signal"},{"key":"B52","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1038\/s41467-020-16886-2","article-title":"Leucine regulates autophagy via acetylation of the mTORC1 component raptor","volume":"11","author":"Son","year":"2020","journal-title":"Nat Commun"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3001737","article-title":"Cytoskeletal vimentin regulates cell size and autophagy through mTORC1 signaling","volume":"20","author":"Mohansundaram","year":"2022","journal-title":"PloS Biol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/bs.ircmb.2024.01.001","article-title":"Targeting signaling pathways in cancer stem cells: a potential approach for developing novel anti-cancer therapeutics","volume":"385","author":"Sinha","year":"2022","journal-title":"Int Rev Cell Mol Biol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24010297","article-title":"The importance of mTORC1-autophagy axis for skeletal muscle diseases","volume":"24","author":"Han","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.65.4.33","article-title":"Mitochondrial DNA-activated cGAS-STING signaling in environmental dry eye","volume":"65","author":"Tan","year":"2024","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1080\/15257770.2024.2311789","article-title":"Cancer stem cells: recent trends in cancer therapy","volume":"43","author":"Amiri-Farsani","year":"2024","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.112512","article-title":"Fut2 deficiency aggravates chronic colitis through 2-oxindole-AHR mediated cGAS-STING pathway","volume":"137","author":"Hong","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1101\/2025.08.25.668405","article-title":"A fibroblast-centric network drives cold fibrosis in the tumor microenvironment of lung squamous cell carcinoma","author":"Miyara","year":"2025","journal-title":"bioRxiv"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.84890","article-title":"The role of cGAS-STING signalling in metabolic diseases: from signalling networks to targeted intervention","volume":"20","author":"Gong","year":"2024","journal-title":"Int J Biol Sci"},{"key":"B61","doi-asserted-by":"crossref","DOI":"10.1101\/2025.04.03.645994","article-title":"A non-canonical cGAS-STING pathway drives cellular and organismal aging","volume-title":"Biorxiv","author":"Cancado de Faria","year":"2025"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2024.2394588","article-title":"The crucial roles and research advances of cGAS-STING pathway in liver diseases","volume":"56","author":"Zhang","year":"2024","journal-title":"Ann Med"},{"key":"B63","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13062-025-00611-4","article-title":"cGAS-STING targeting offers therapy choice in lung diseases","volume":"20","author":"Wang","year":"2025","journal-title":"Biol Direct"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2023.156422","article-title":"Role of cGAS-STING in colorectal cancer: a new window for treatment strategies","volume":"173","author":"Khorasani","year":"2023","journal-title":"Cytokine"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.66.15.48","article-title":"Cyclosporine A ameliorates inflammatory responses in dry eye by inactivating cGAS-STING signaling via the initiation of autophagy","volume":"66","author":"Han","year":"2025","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-22-3034","article-title":"Mesenchymal-like tumor cells and myofibroblastic cancer-associated fibroblasts are associated with progression and immunotherapy response of clear cell renal cell carcinoma","volume":"83","author":"Davidson","year":"2023","journal-title":"Cancer Res"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.18632\/aging.205128","article-title":"Single-cell landscape and spatial transcriptomic analysis reveals macrophage infiltration and glycolytic metabolism in kidney renal clear cell carcinoma","volume":"15","author":"Wen","year":"2023","journal-title":"Aging (Albany NY)"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1352632","article-title":"Investigating the complex interplay between fibroblast activation protein \u03b1-positive cancer associated fibroblasts and the tumor microenvironment in the context of cancer immunotherapy","volume":"15","author":"Kraxner","year":"2025","journal-title":"Front Immunol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1274781","article-title":"Targeting STAT3 in tumor-associated antigen-presenting cells as a strategy for kidney and bladder cancer immunotherapy","volume":"14","author":"Alcantara","year":"2023","journal-title":"Front Immunol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000548773","article-title":"Evaluating urinary biomarkers for early detection of kidney damage in immune checkpoint inhibitors-treated patients","author":"Casanova","year":"2025","journal-title":"Am J Nephrol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-019-05869-7","article-title":"Lung-kidney interactions in critically ill patients: consensus report of the Acute Disease Quality Initiative (ADQI) 21 Workgroup","volume":"46","author":"Joannidis","year":"2020","journal-title":"Intensive Care Med"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13112733","article-title":"Vitamin D as a systemic regulatory axis: From homeostasis to multiorgan disease","volume":"13","author":"Rodr\u00edguez-Rivero","year":"2025","journal-title":"Biomedicines"},{"key":"B73","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1080\/1750743X.2025.2516995","article-title":"Mitigation strategies for gastrointestinal (GI) immune-related adverse events for patients with solid tumors receiving immunotherapy","volume":"17","author":"Lasagna","year":"2025","journal-title":"Immunotherapy"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.1c02391","article-title":"Immunosuppressive nanoparticles for management of immune-related adverse events in liver","volume":"15","author":"Shen","year":"2021","journal-title":"ACS Nano"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaf191","article-title":"Practice patterns and outcomes in cancer patients developing immune checkpoint inhibitors-related AKI","author":"Blanchette","year":"","journal-title":"Nephrol Dial Transplant"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1002\/cbic.202400255","article-title":"STING-activating small molecular therapeutics for cancer immunotherapy","volume":"25","author":"Huang","year":"2024","journal-title":"ChemBioChem"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1080\/0886022X.2025.2569089","article-title":"Immune checkpoint inhibitor-induced nephrotic syndrome: a pharmacovigilance analysis of 404 FAERS cases and literature case series","volume":"47","author":"Ye","year":"2025","journal-title":"Ren Fail"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1221135","article-title":"Biopsy-proven acute tubulointerstitial nephritis in patients treated with immune checkpoint inhibitors: a pooled analysis of case reports","volume":"13","author":"Esposito","year":"2023","journal-title":"Front Oncol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006127","article-title":"First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817","volume":"11","author":"Ready","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.172569","article-title":"Urine proteomic signatures of histological class, activity, chronicity, and treatment response in lupus nephritis","volume":"9","author":"Fava","year":"2024","journal-title":"JCI Insight"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1177\/10781552241252627","article-title":"Diagnosis, management, and outcomes of immune checkpoint inhibitor induced acute interstitial nephritis: A single-center experience","volume":"31","author":"Elghawy","year":"2025","journal-title":"J Oncol Pharm Pract"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1777694\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T05:38:28Z","timestamp":1783661908000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1777694\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":81,"alternative-id":["10.3389\/fimmu.2026.1777694"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1777694","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"article-number":"1777694"}}